SARS-CoV-2 Spike RBD Nanobody, Unconjugated, Camelus, Monoclonal

Produktübersicht

• Artikelname: SARS-CoV-2 Spike RBD Nanobody, Unconjugated, Camelus, Monoclonal
• Artikelnummer: CSB-RA33245A2GMY
• Hersteller Artikelnummer: CSB-RA33245A2GMY
• Alternativnummer: CSB-RA33245A2GMY-100UL, CSB-RA33245A2GMY-50UL
• Hersteller: Cusabio
• Wirt: Camelus
• Kategorie: Antikörper
• Applikation: ELISA, GICA, NeA
• Spezies Reaktivität: Virus
• Konjugation: Unconjugated
• Alternative Synonym: S, S1, S1-RBD, Spike glycoprotein, sars-cov-2

Produkteigenschaften

• Klonalität: Monoclonal
• UniProt: P0DTC2
• Puffer: Preservative: 0.03% Proclin 300<br />Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
• Reinheit: Affinity-chromatography
• Formulierung: Liquid
• Target-Kategorie: S
• Antibody Type: Recombinant Antibody

Anwendungsbeschreibung

• Application Verdünnung: Recommended dilution: ELISA:1:10000-1:100000, GICA:1:10000-1:40000, Neutralising:1:100-1:10000

Bilder

In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.

ELISA: Immobilize various types of SARS proteins at concentration of 2µg/ml on solid substrate, then react with SARS-CoV-2 Spike RBD Nanobody at concentration of 100µg/ml, 10µg/ml and 1µg/ml. It shows the SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) is specific for SARS-CoV-2-S1-RBD protein, without any cross-reactivity with MERS-CoV, SARS-CoV, HCoV-OC43 or HCoV-229E.

The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD
Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) at 2 µg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml.

SARS-CoV-2 Spike protein RBD His/Sumostar Tag (CSB-YP3324GMY1) captured on COOH chip binding to the SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY), increases the local refractive index (RI), leading to a red shift of the LSPR peak position. The higher concentrations of SARS-CoV-2 Spike RBD Nanobody, the larger the wavelength shift. The detected affinity constant of SARS-CoV-2 Spike protein RBD/SARS-CoV-2 Spike RBD Nanobody binding is 28.2nM.

SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) competed with ACE2-HRP conjugate (CSB-MP866317HU) for binding to SARS-CoV-2-S1-RBD (CSB-YP3324GMY1). The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARS-CoV-2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.

SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) competitively prevented SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) from binding to ACE2-HRP conjugate (CSB-MP866317HU). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the SARS-CoV-2 Spike RBD Nanobody concentrations. It showed that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC50 of this SARS-CoV-2 Spike RBD Nanobody is 0.1074 µg/ml.